We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+2.35%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$7.07B
AUM Growth
+$212M
Cap. Flow
+$369M
Cap. Flow %
5.23%
Top 10 Hldgs %
69.18%
Holding
43
New
7
Increased
10
Reduced
7
Closed
4

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$109M
2
ALKS icon
Alkermes
ALKS
+$70.4M
3
VERA icon
Vera Therapeutics
VERA
+$57.6M
4
ARWR icon
Arrowhead Research
ARWR
+$45.8M
5
MRUS
Merus
MRUS
+$37M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$38.5M
2
UTHR icon
United Therapeutics
UTHR
+$36.2M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$27.6M
4
DYN icon
Dyne Therapeutics
DYN
+$23.3M
5
KURA icon
Kura Oncology
KURA
+$18.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.9B
$974M 13.78%
2,760,300
-98,588
-3% -$36.2M
ARGX icon
2
argenx
ARGX
$54.9B
$762M 10.77%
1,238,467
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$16.6B
$703M 9.94%
5,103,055
+114,167
+2% +$15M
MDGL icon
4
Madrigal Pharmaceuticals
MDGL
$12.4B
$626M 8.86%
2,029,000
– –
KRYS icon
5
Krystal Biotech
KRYS
$10.6B
$412M 5.83%
2,628,822
+6,600
+0.3% +$1.17M
APLS
6
DELISTED
Apellis Pharmaceuticals
APLS
$390M 5.52%
12,222,222
+1,111,111
+10% +$33.4M
SRPT icon
7
Sarepta Therapeutics
SRPT
$1.64B
$311M 4.4%
2,555,555
– –
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$255M 3.6%
3,050,000
– –
VERA icon
9
Vera Therapeutics
VERA
$2.31B
$237M 3.36%
5,610,000
+1,300,410
+30% +$57.6M
XENE icon
10
Xenon Pharmaceuticals
XENE
$6.15B
$222M 3.14%
5,666,666
– –
FOLD
11
DELISTED
Amicus Therapeutics
FOLD
$218M 3.09%
23,175,000
– –
RNAM
12
DELISTED
Avidity Biosciences
RNAM
$218M 3.08%
7,500,000
+625,000
+9% +$26.1M
ARWR icon
13
Arrowhead Research
ARWR
$11.9B
$209M 2.95%
11,111,111
+2,222,223
+25% +$45.8M
KYMR icon
14
Kymera Therapeutics
KYMR
$8.6B
$207M 2.93%
5,150,000
+650,000
+14% +$29.4M
MLTX icon
15
MoonLake Immunotherapeutics
MLTX
$1.58B
$150M 2.12%
2,770,100
– –
SLNO
16
DELISTED
Soleno Therapeutics
SLNO
$113M 1.61%
2,525,000
+344,000
+16% +$17.8M
BPMC
17
DELISTED
Blueprint Medicines
BPMC
$103M 1.46%
+1,185,000
New +$109M
PCVX icon
18
Vaxcyte
PCVX
$7.61B
$96.2M 1.36%
1,175,000
– –
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.9B
$96.1M 1.36%
1,462,500
-575,515
-28% -$38.5M
MRUS
20
DELISTED
Merus
MRUS
$89.4M 1.26%
2,125,000
+770,000
+57% +$37M
BCRX icon
21
BioCryst Pharmaceuticals
BCRX
$2.43B
$89.2M 1.26%
11,865,000
– –
ALKS icon
22
Alkermes
ALKS
$8.08B
$70.5M 1%
+2,450,000
New +$70.4M
OCUL icon
23
Ocular Therapeutix
OCUL
$1.84B
$68.8M 0.97%
8,060,000
– –
MNKD icon
24
MannKind Corp
MNKD
$1.2B
$56.3M 0.8%
8,750,000
– –
TRML
25
DELISTED
Tourmaline Bio
TRML
$45.1M 0.64%
2,222,222
– –
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2024 Portfolio in Review

As of Q4 2024, Avoro Capital Advisors held 43 positions worth $7.07B, up 3.1% from $6.86B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors deployed $369M of net new capital in Q4 2024, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Blueprint Medicines: 1,185,000 shares worth $103M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $38.5M trimmed.

  • Avoro Capital Advisors's largest Q4 2024 buy was Blueprint Medicines: 1,185,000 shares worth $103M.
  • Avoro Capital Advisors added most to Vera Therapeutics in Q4 2024, an estimated $57.6M increase.
  • Avoro Capital Advisors's biggest Q4 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $38.5M.
  • Avoro Capital Advisors fully exited Dyne Therapeutics in Q4 2024, selling an estimated $23.3M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $7.07B portfolio in Q4 2024.
  • Avoro Capital Advisors opened 7 new positions and closed 4 in Q4 2024.
  • Avoro Capital Advisors's portfolio value rose 3.1% quarter-over-quarter to $7.07B.

Based on Avoro Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.